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The Janus kinases (JAKs) are essential for cytokine
receptor signalling and their dephosphorylation rep-
resents a potent inhibitory mechanism. A new paper
highlights the T-cell tyrosine phosphatase as an
important JAK inhibitor.
The Janus kinases (JAKs), and the signal transducer
and activator of transcription proteins (STATs) that are
regulated by these kinases, have critical roles in cell
differentiation, proliferation, malignant transformation,
survival and host resistance to pathogens [1,2]. The
JAK family contains four members, Jak1, Jak2, Jak3
and Tyk2, which are differentially regulated in
response to various cytokines. Jak3 is mainly found in
haematopoietic cells, whereas the other three
members of the family are more widely expressed.
JAKs are constitutively associated with the cytoplas-
mic domains of cytokine receptors. Ligand binding to
the receptor triggers dimerisation, thereby bringing
together two JAKs that are then activated by
transphosphorylation. Phosphorylation occurs at two
conserved tyrosine residues in the activation loop of
the JAKs and mutation of these residues leads to an
inactive kinase. Considerable interest has therefore
focused on the identification of the tyrosine phos-
phatases that may dephosphorylate these phospho-
tyrosines, thereby downregulating cytokine signalling
pathways. The question of whether each JAK is
dephosphorylated by a different tyrosine phosphatase
or whether one enzyme carries out this task for the
whole family is another important issue.
A paper from the McGlade laboratory [3], recently
published in Current Biology, now suggests a new
candidate phosphatase for the role of JAK ‘dephos-
phorylater-in-chief’ — the T-cell protein tyrosine phos-
phatase (TCPTP) [4]. Interestingly, TCPTP shows
selectivity towards Jak1 and Jak3, suggesting that
phosphatases are indeed specialised to regulate dif-
ferent JAKs. Two main strategies were adopted to
establish Jak1 and Jak3 as TCPTP substrates. First, a
‘trapping mutant’ of the enzyme was used to identify
putative substrates. All protein tyrosine phosphatases
contain a conserved catalytic aspartic acid residue
which facilitates protonation of the phenolic atom of
the tyrosyl leaving group during phosphate cleavage.
Mutation of this residue to an alanine generates a
phosphatase-inactive ‘substrate trap’ form of the
enzyme that binds to putative substrates but does not
release them, so facilitating substrate identification [5].
Using this approach the McGlade group demon-
strated that tyrosine phosphorylated Jak1 and Jak3,
but not Jak2, selectively bound to the trapping mutant
version of TCPTP [3]. Binding was prevented by 
the addition of orthovanadate, a potent competitive
inhibitor of tyrosine phosphatases, confirming that
trapping was occurring via the catalytic domain rather
than via some other motif. The impressive discrimina-
tion of trapping assays was demonstrated by the fact
that trapping mutants of two other tyrosine phos-
phatases, PTP-PEST and PTP-1B, failed to interact
with either Jak1 or Jak3. Furthermore, co-transfection
of enzymatically active TCPTP with either Jak1 or
Jak3 readily caused their dephosphorylation in a cell-
based system.
The second approach used to establish Jak1 and
Jak3 as TCPTP substrates was to investigate the
phosphorylation and activation state of JAKs and
STATs in cells from TCPTP-deficient mice. Despite its
name, TCPTP is widely expressed in many cell types,
with particularly high expression in haematopoietic
cells, so unsurprisingly the complex TCPTP-deficient
phenotype is characterised by defects in multiple lin-
eages [6]. Using primary TCPTP-deficient cells, the
McGlade group found that both Stat1 and Stat5 are
hyperphosphorylated, suggesting that TCPTP nor-
mally downregulates these pathways. Furthermore, in
short-term TCPTP-deficient macrophage cultures,
Jak1 but not Jak2 was found to be hyperphosphory-
lated, consistent with a selective role for TCPTP in
dephosphorylating Jak1, as suggested by the trapping
results. However, the various results obtained on JAKs
and STATs from the TCPTP-deficient mice were from
three different cell types (thymocytes, mature T cells
and macrophages). Therefore a tight correlation
between hyperphosphorylation of a JAK and a STAT
in a single cytokine signalling pathway has yet to be
elucidated using primary TCPTP-deficient cells. Nev-
ertheless, the trapping mutant and primary TCPTP-
deficient cell data taken together [3] do suggest that
Jak1 and Jak3 are relevant TCPTP substrates in vivo.
Do these findings help to explain the phenotype of
TCPTP-deficient mice? Here the situation becomes
more tricky. Whereas T-cell development is only mildly
perturbed in TCPTP-deficient mice, B-cell develop-
ment is markedly affected [6]. However, adoptive
transfer of TCPTP-deficient bone marrow cells into a
wild-type irradiated host, allowed both B and T cells to
develop normally, pointing to a defect in the ability of
TCPTP-deficient stromal cells to support normal lym-
phoid cell development. Despite this, mature TCPTP-
deficient T and B cells displayed striking defects in
their ability to respond to mitogens irrespective of
whether they had developed in a TCPTP-deficient or
wild-type stromal cell environment [6]. If Jak1 and Jak3
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are key substrates for TCPTP, then this seems rather
surprising, for both these kinases have been implicated
in the interleukin-2 (IL-2) receptor signalling pathway
that promotes T-cell proliferation, and in the absence
of the negative regulatory actions of TCPTP one might
therefore have expected lymphocyte hyperresponsive-
ness. Perhaps TCPTP has a separate positive role in
lymphocyte signalling involving the dephosphorylation
of a negatively acting molecule that acts further
upstream than the JAKs in the cascade of events
leading to activation. An analogous situation would be
the suggested role of the SHP-2 tyrosine phosphatase
in positively regulating the coupling of the T-cell
antigen receptor to the Ras/MAP kinase pathway by
dephosphorylating a negatively acting substrate [7].
Even the powerfully mitogenic combination of phorbol
ester plus ionomycin is unable to restore TCPTP-defi-
cient splenic T-cell mitogenesis [4], so any putative
positive action of TCPTP must presumably occur
downstream of protein kinase C and calcium. In this
context an early paper showing that human TCPTP
can complement the mitotic activator Cdc25 [8] is of
interest and cell-cycle analysis using cells from
TCPTP-deficient mice could prove rewarding.
The idea of a tyrosine phosphatase that could play
distinctive roles in receptor signalling and in cell-cycle
regulation highlights the issue of subcellular localisa-
tion. Alternative splicing of TCPTP generates two
forms of the enzyme, TCPTPa (45kDa) and TCPTPb
(48kDa), which appear to localise to the nucleus and
the endoplasmic reticulum, respectively [9,10]. So how
does TCPTP reach its putative JAK substrates given
that they are associated with the cytoplasmic tails of
cytokine receptors? A possible scenario is suggested
by a study using EGF-responsive cells in which it was
shown that mitogenic stimulation caused the migra-
tion of a significant proportion of TCPTP from the
nucleus to the cytoplasm [11]. It would be of interest
to know whether a similar TCPTP translocation occurs
upon antigen receptor stimulation in lymphocytes.
Not surprisingly, there are a number of other candi-
date JAK tyrosine phosphatases competing for
supremacy in the dephosphorylation sweepstakes, as
Figure 1 illustrates. A trapping mutant of PTP1B, a
tyrosine phosphatase having a high level of homology
to TCPTP in its catalytic domain, interacts with Jak2
and Tyk2, but not with Jak1, further underlining phos-
phatase substrate specificity [12]. Distinctive roles for
PTP1B and TCPTP are also suggested by the PTP1B
knockout phenotype which is characterised by resis-
tance to diet-induced obesity and diabetes [13], in
contrast to the haematopoietic abnormalities of
TCPTP-deficient mice [6]. Whereas TCPTP and
PTP1B appear to be neatly complementary with
regard to their specificity, the CD45 transmembrane
tyrosine phosphatase [14], restricted in its expression
to haematopoietic cells, appears to be capable of
dephosphorylating all four JAK family members [15]. 
So which phosphatase is more important in regulat-
ing JAKs in haematopoietic cells? It is too early to say,
but the answer may turn out to be ‘it all depends on
timing’. CD45 is abundant at the cell surface, so may
be used to maintain the cytokine receptor associated
pools of JAKs in a low activity state, protecting cells
from inappropriate stimulation. In contrast TCPTP
could be released from the nucleus to the cytoplasm,
following cytokine stimulation and consequent JAK
phosphorylation, to act as a classical feedback
inhibitor. Earlier literature has also drawn attention to
the SHP tyrosine phosphatases as possible JAK reg-
ulators (reviewed in [1,2]). There is good evidence that
both SHP-1 [16–18] and SHP-2 [19,20] can bind to
JAKs and/or be recruited to cytokine receptors, acting
as negative regulators of cytokine signalling path-
ways. However, the binding of JAKs to trapping
mutants of these enzymes has not yet been reported,
leaving open the question as to whether the main
action of the SHPs might be to regulate cytokine
receptors rather than JAK dephosphorylation.
Following stimulation, receptor cytoplasmic tails are
like busy docking sites where the arrival and depar-
ture of molecules are carefully orchestrated. From an
evolutionary perspective, the JAKs play such a key
role in this process in cytokine receptor signalling that
the high-risk strategy of leaving the task of JAK de-
activation to a single tyrosine phosphatase appears
Figure 1. The tyrosine phosphatases that
regulate the JAK family.
The JAKs constitutively associate with
cytokine receptors. In reality more than
one JAK may associate with a particular
receptor. The model suggests that CD45
dephosphorylates receptor-associated
JAK pools, so maintaining low basal
activity and preventing inappropriate
receptor stimulation. Following receptor
engagement, the JAKs are tyrosine phos-
phorylated and activated. TCPTP and
PTP1B may then be recruited to the
receptor to exert feedback inhibitory
effects by dephosphorylating selected
JAKs. The SHP-1 and SHP-2 tyrosine
phosphatases have also been implicated
in the regulation of cytokine receptor sig-
nalling, in some cases by associating with JAKs. However, they have not yet definitively been shown to act as JAK phosphatases.
Also SHP-2 has been suggested to exert a positive rather than negative role in cytokine signalling in some experimental systems.
Note that the model combines data from several different cell types.
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unlikely. The next challenge is to determine how the
various phosphatases jostling at the docking site
function in subcellular time and space.
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